Phase 3 Metabolic & Obesity Deal Benchmarks

Median Upfront

$1.4B

Range: $928M - $1.9B

Total Deal Value

$5.3B

Range: $4.0B - $6.7B

Royalty Rate

19.4% - 30%

Tiered up to 35%

Dev Milestones

$312M

Range: $246M - $384M

Model Your Deal

Market Analysis

Phase 3 metabolic & obesity licensing deals carry a median total deal value of $5.3B, with upfront payments ranging from $928M to $1.9B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 27% to upfront and 73% to milestones.

The metabolic & obesity landscape at the phase 3 stage is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Development milestones average $312M, regulatory milestones contribute $663M, and commercial milestones reach $2.9B. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations.

Royalty rates for phase 3 metabolic & obesity deals range from 19.4% to 30% at the base tier, with high-tier escalation to 35%. The reduced risk profile at this stage justifies higher fixed royalty commitments.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 3 metabolic & obesity deals?

Phase 3 metabolic & obesity deals average $1.4B in upfront payments, ranging from $928M to $1.9B. The upfront allocation of 27% of total deal value reflects the clinical stage risk profile.

How are phase 3 metabolic & obesity deal milestones structured?

Milestones account for approximately 73% of total deal value. Development milestones ($312M) represent the largest component, followed by commercial milestones ($2.9B) and regulatory milestones ($663M).

What royalty rates are typical for phase 3 metabolic & obesity licensing?

Base royalty rates range from 19.4% to 30%, with tiered escalation to 23.4%-35% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 3 Metabolic & Obesity Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Metabolic & Obesity Deals

Phase 1 Metabolic & Obesity Deals

Phase 3 Oncology Deals

Phase 3 Neurology Deals

Ready to Calculate Your Deal Terms?